作者
Ivan FN Hung, Kelvin KW To, Cheuk-Kwong Lee, Kar-Lung Lee, Wing-Wa Yan, Kenny Chan, Wai-Ming Chan, Chun-Wai Ngai, Kin-Ip Law, Fu-Loi Chow, Raymond Liu, Kang-Yiu Lai, Candy CY Lau, Shao-Haei Liu, Kwok-Hung Chan, Che-Kit Lin, Kwok-Yung Yuen
发表日期
2013/8/1
期刊
Chest
卷号
144
期号
2
页码范围
464-473
出版商
Elsevier
简介
Background
Experience from influenza pandemics suggested that convalescent plasma treatment given within 4 to 5 days of symptom onset might be beneficial. However, robust treatment data are lacking.
Methods
This is a multicenter, prospective, double-blind, randomized controlled trial. Convalescent plasma from patients who recovered from the 2009 pandemic influenza A(H1N1) (A[H1N1]) infection was fractionated to hyperimmune IV immunoglobulin (H-IVIG) by CSL Biotherapies (now BioCSL). Patients with severe A(H1N1) infection on standard antiviral treatment requiring intensive care and ventilatory support were randomized to receive H-IVIG or normal IV immunoglobulin manufactured before 2009 as control. Clinical outcome and adverse effects were compared.
Results
Between 2010 and 2011, 35 patients were randomized to receive H-IVIG (17 patients) or IV immunoglobulin (18 patients). One defaulted …
学术搜索中的文章
IFN Hung, KKW To, CK Lee, KL Lee, WW Yan, K Chan… - Chest, 2013